A citation-based method for searching scientific literature

J S Penn, A Madan, R B Caldwell, M Bartoli, R W Caldwell, M E Hartnett. Prog Retin Eye Res 2008
Times Cited: 438







List of co-cited articles
737 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.
Massimo Nicolò, Lorenzo Ferro Desideri, Aldo Vagge, Carlo Enrico Traverso. Expert Opin Investig Drugs 2021
16
6

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study.
Quan Dong Nguyen, Syed Mahmood Shah, Afsheen A Khwaja, Roomasa Channa, Elham Hatef, Diana V Do, David Boyer, Jeffery S Heier, Prema Abraham, Allen B Thach,[...]. Ophthalmology 2010
364
1

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.
S A Stacker, C Caesar, M E Baldwin, G E Thornton, R A Williams, R Prevo, D G Jackson, S Nishikawa, H Kubo, M G Achen. Nat Med 2001
945
1


Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study.
Xiaoxin Li, Hong Dai, Xiaorong Li, Mei Han, Jun Li, Andrea Suhner, Renxin Lin, Sebastian Wolf. Graefes Arch Clin Exp Ophthalmol 2019
10
10


Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes.
John F Payne, Charles C Wykoff, W Lloyd Clark, Beau B Bruce, David S Boyer, David M Brown. Am J Ophthalmol 2019
30
3

Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial.
Chelsea Fechter, Heather Frazier, William B Marcus, Amina Farooq, Harinderjit Singh, Dennis M Marcus. Ophthalmic Surg Lasers Imaging Retina 2016
10
10



Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.
Yasir J Sepah, Mohammad Ali Sadiq, David Boyer, David Callanan, Ron Gallemore, Michael Bennett, Dennis Marcus, Lawrence Halperin, Muhammad Hassan, Peter A Campochiaro,[...]. Ophthalmology 2016
20
5

Factors associated with 1-year visual response following intravitreal bevacizumab treatment for diabetic macular edema: a retrospective single center study.
Janejit Choovuthayakorn, Apichat Tantraworasin, Phichayut Phinyo, Jayanton Patumanond, Paradee Kunavisarut, Titipol Srisomboon, Pawara Winaikosol, Direk Patikulsila, Voraporn Chaikitmongkol, Nawat Watanachai,[...]. Int J Retina Vitreous 2021
4
25

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Teri N Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Cheryl Royce, Irene Stroud, Nancy Garren, Megan Mackey, John A Butman, Kevin Camphausen,[...]. J Clin Oncol 2009
1

One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.
Fengjiao Li, Le Zhang, Yanling Wang, Wenwen Xu, Wanzhen Jiao, Aihua Ma, Bojun Zhao. Curr Eye Res 2018
30
3

Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis.
Matteo Fallico, Andrea Maugeri, Andrew Lotery, Antonio Longo, Vincenza Bonfiglio, Andrea Russo, Teresio Avitabile, Alfredo Pulvirenti, Claudio Furino, Gilda Cennamo,[...]. Acta Ophthalmol 2021
9
11

VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor.
M Ali Behzadian, L Jack Windsor, Nagla Ghaly, Gregory Liou, Nai-Tse Tsai, Ruth B Caldwell. FASEB J 2003
100
1

The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.
Es Rennel, E Waine, H Guan, Y Schüler, W Leenders, J Woolard, M Sugiono, D Gillatt, Es Kleinerman, Do Bates,[...]. Br J Cancer 2008
104
1

Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
Daisuke Watanabe, Kiyoshi Suzuma, Shigeyuki Matsui, Masafumi Kurimoto, Junichi Kiryu, Mihori Kita, Izumi Suzuma, Hirokazu Ohashi, Tomonari Ojima, Tomoaki Murakami,[...]. N Engl J Med 2005
341
1

Bevacizumab for the management of diabetic macular edema.
Francisco Rosa Stefanini, J Fernando Arevalo, Maurício Maia. World J Diabetes 2013
23
4

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
M Jeltsch, A Kaipainen, V Joukov, X Meng, M Lakso, H Rauvala, M Swartz, D Fukumura, R K Jain, K Alitalo. Science 1997
1

Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis.
Hideyasu Oh, Hitoshi Takagi, Atsushi Otani, Shinji Koyama, Seiji Kemmochi, Akiyoshi Uemura, Yoshihito Honda. Proc Natl Acad Sci U S A 2002
130
1

c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro.
L Marconcini, S Marchio, L Morbidelli, E Cartocci, A Albini, M Ziche, F Bussolino, S Oliviero. Proc Natl Acad Sci U S A 1999
213
1

Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
John Lowe, James Araujo, Jihong Yang, Mike Reich, Amy Oldendorp, Vanessa Shiu, Valerie Quarmby, Henry Lowman, Samantha Lien, Jacques Gaudreault,[...]. Exp Eye Res 2007
112
1

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
Michel Michaelides, Andrew Kaines, Robin D Hamilton, Samantha Fraser-Bell, Ranjan Rajendram, Fahd Quhill, Christopher J Boos, Wen Xing, Catherine Egan, Tunde Peto,[...]. Ophthalmology 2010
327
1

Emerging drugs for the treatment of diabetic retinopathy.
Elio Striglia, Andrea Caccioppo, Niccolò Castellino, Michele Reibaldi, Massimo Porta. Expert Opin Emerg Drugs 2020
4
25

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Christos Haritoglou, Daniel Kook, Aljoscha Neubauer, Armin Wolf, Siegfried Priglinger, Rupert Strauss, Arnd Gandorfer, Michael Ulbig, Anselm Kampik. Retina 2006
314
1

Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review.
Yiran Tan, Akira Fukutomi, Michelle T Sun, Shane Durkin, Jagjit Gilhotra, Weng Onn Chan. Surv Ophthalmol 2021
5
20

Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach.
Chiara B M Platania, Luisa Di Paola, Gian M Leggio, Giovanni L Romano, Filippo Drago, Salvatore Salomone, Claudio Bucolo. Front Pharmacol 2015
57
1


Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 μg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I).
Michael A Singer, Dan M Miller, Jeffrey G Gross, Craig M Greven, Barry Kapik, Clare Bailey, Faruque Ghanchi, Baruch D Kuppermann. Ophthalmic Surg Lasers Imaging Retina 2018
6
16


Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
João Figueira, Emily Fletcher, Pascale Massin, Rufino Silva, Francesco Bandello, Edoardo Midena, Monica Varano, Sobha Sivaprasad, Haralabos Eleftheriadis, Geeta Menon,[...]. Ophthalmology 2018
49
2

Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Jihong Yang, Xiangdan Wang, Germaine Fuh, Lanlan Yu, Eric Wakshull, Mehraban Khosraviani, Eric S Day, Barthélemy Demeule, Jun Liu, Steven J Shire,[...]. Mol Pharm 2014
60
1

DARPins: a new generation of protein therapeutics.
Michael T Stumpp, H Kaspar Binz, Patrick Amstutz. Drug Discov Today 2008
142
1


Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.
Maureen G Maguire, Danni Liu, Adam R Glassman, Lee M Jampol, Chris A Johnson, Carl W Baker, Neil M Bressler, Thomas W Gardner, Dante Pieramici, Cynthia R Stockdale,[...]. JAMA Ophthalmol 2020
15
6


Neovascular Glaucoma.
Shane J Havens, Vikas Gulati. Dev Ophthalmol 2016
38
2

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
Peter A Campochiaro, David M Brown, Andrew Pearson, Thomas Ciulla, David Boyer, Frank G Holz, Michael Tolentino, Amod Gupta, Lilianne Duarte, Steven Madreperla,[...]. Ophthalmology 2011
246
1


Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
Raj K Maturi, Adam R Glassman, Kristin Josic, Andrew N Antoszyk, Barbara A Blodi, Lee M Jampol, Dennis M Marcus, Daniel F Martin, Michele Melia, Hani Salehi-Had,[...]. JAMA Ophthalmol 2021
20
5

Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: Current research and future perspectives.
Joana Mesquita, João Paulo Castro-de-Sousa, Sara Vaz-Pereira, Arminda Neves, Luís A Passarinha, Cândida T Tomaz. Cytokine Growth Factor Rev 2018
21
4

Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.
John F Payne, Charles C Wykoff, W Lloyd Clark, Beau B Bruce, David S Boyer, David M Brown. Br J Ophthalmol 2021
2
50

Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.
Ruth B Caldwell, Manuela Bartoli, M Ali Behzadian, Azza E B El-Remessy, Mohamed Al-Shabrawey, Daniel H Platt, Gregory I Liou, R William Caldwell. Curr Drug Targets 2005
169
1

Autoimmune retinopathy and antiretinal antibodies: a review.
Dilraj S Grewal, Gerald A Fishman, Lee M Jampol. Retina 2014
77
1

Tgfbi/Bigh3 silencing activates ERK in mouse retina.
Nathalie Allaman-Pillet, Anne Oberson, Mauro Bustamante, Andrea Tasinato, Edith Hummler, Daniel F Schorderet. Exp Eye Res 2015
6
16

Reactome pathway analysis: a high-performance in-memory approach.
Antonio Fabregat, Konstantinos Sidiropoulos, Guilherme Viteri, Oscar Forner, Pablo Marin-Garcia, Vicente Arnau, Peter D'Eustachio, Lincoln Stein, Henning Hermjakob. BMC Bioinformatics 2017
245
1

Mutation update: TGFBI pathogenic and likely pathogenic variants in corneal dystrophies.
Valeria Kheir, Vianney Cortés-González, Juan C Zenteno, Daniel F Schorderet. Hum Mutat 2019
18
5

A role for Nr-CAM in the patterning of binocular visual pathways.
Scott E Williams, Martin Grumet, David R Colman, Mark Henkemeyer, Carol A Mason, Takeshi Sakurai. Neuron 2006
67
1


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.